RxDoctor Payments Data

Philip Perilstein, MD

Family Medicine · Warmisnter, PANPI 1841294220

Payments from drug & device makers

$4,084in general payments, 2019–2025

Across 208 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$737
  • Novo Nordisk$724
  • Lilly USA, LLC$563
  • Merck$371
  • GSK$313
  • Amgen$155
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$4,084100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,084 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$155,415
Medicare patients
229
Services billed
1,579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$88,353
TrulicityDulaglutide39$78,337
EliquisApixaban38$43,864
XareltoRivaroxaban29$27,184
JardianceEmpagliflozin25$24,764
MounjaroTirzepatide15$21,837
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,931
Atorvastatin Calcium553$6,477
SymbicortBudesonide/Formoterol Fumarate14$5,452
Levothyroxine Sodium203$2,864
Pravastatin Sodium88$2,546
SynthroidLevothyroxine Sodium30$2,346
Ezetimibe68$2,216
Tamsulosin Hcl115$2,178
Metformin Hcl ErMetformin Hcl153$2,175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$563$100,17354 claims
Novo NordiskOzempic$724$88,35363 claims
PfizerEliquis$133$43,86438 claims
Johnson & JohnsonXarelto$148$27,18429 claims
Boehringer IngelheimJardiance$62$24,76425 claims
GSKTrelegy Ellipta$313$14,93115 claims
AstraZenecaSymbicort$737$5,45214 claims
AbbVieSynthroid$96$2,34630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Warmisnter

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →